Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques

Vaccine

Volumn 19, Issue 27, 2001, Pages 3700-3709

  Stittelaar, Koert J ^a,b   Kuiken, Thijs ^a   De Swart, Rik L ^a   Van Amerongen, Geert ^b   Vos, Helma W ^a   Niesters, Hubert G M ^a   Van Schalkwijk, Pim ^a   Van Der Kwast, Theo ^a   Wyatt, Linda S ^c   Moss, Bernard ^c   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Macaques; Modified vaccinia virus Ankara; Smallpox

Indexed keywords

THYMOCYTE ANTIBODY; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; IMMUNE DEFICIENCY; INOCULATION; MACACA; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, VIRAL; DNA, VIRAL; FEMALE; GENOME, VIRAL; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INJECTIONS, INTRADERMAL; MACACA FASCICULARIS; POLYMERASE CHAIN REACTION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0035859306     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00075-5     Document Type: Article

References (35)

1. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism
2. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
3. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
4. Host range and cytopathologenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
5. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells
6. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model
7. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
8. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
9. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies
10. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein
11. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
12. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
13. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors
14. The complete genomic sequence of the modified vaccinia ankara strain: Comparison with other orthopoxviruses
15. Protective immunity in macaques vaccinated with a Modified Vaccinia virus Ankara-based measles vaccine in the presence of passively acquired antibodies
16. Vaccination with Rev and Tat against AIDS
17. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine
18. Immunosenescence: Impact in the young as well as the old?
19. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
20. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine
21. Studies on poxvirus infections in irradiated animals
22. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola
23. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells
24. Dosimetry for total body irradiation of rhesus monkeys with 300 kV X-rays
25. Serological and virological characterization of clinically diagnosed cases of measles in suburban Khartoum
26. Measles in a Dutch hospital introduced by an immunocompromised infant from Indonesia infected with a new genotype virus
27. Viral replication and development of specific immunity in macaques after infection with different measles virus strains
28. Cowpox: Reservoir hosts and geographic range
29. Progressive Vaccinia in immunologically deficient individuals
30. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: Involvement of nonproteasomal cytosolic proteases in antigen processing?
31. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection
32. Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production
33. T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella
34. Immune responses during measles infection in immunosuppressed rhesus monkeys
35. Experimental measles I. Pathogenesis in the normal and the immunized host